Opinion|Videos|November 22, 2024
Future Treatment Landscape for EGFR-mutated Non-Small Cell Lung Cancer
Author(s)Hatim Husain, MD
Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists for optimizing patient care in this rapidly changing field.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What do you see as the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer (NSCLC)?
- What are the current unmet needs in the treatment of EGFR-mutant advanced NSCLC?
- What clinical pearls could you share with community oncologists in the treatment of EGFR-mutant advanced NSCLC?
Advertisement
Related to this article
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.
The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.
Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.
Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.
First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
3
Mosunetuzumab Combo Improves PFS in R/R Follicular Lymphoma
4
FDA Launches Expedited IND Pilot to Speed First-in-Human Trials
5